Imaging-Based Precision Medicine with 177Lu-PSMA-617 in Advanced Prostate Cancer – Who Will Benefit?

Prostate-Specific Membrane Antigen Imaging Before and After 177Lu-PSMA-617 Treatment

After previously reporting effective results from 177LU-PSMA-617 treatment in patients with metastatic castration-resistant prostate cancer (mCRPC), Jones T. Nauseef, MD, PhD, sought to refine...

Curated Journal reading List

Advertisement
Advertisement

Expert Interviews